Loading patent…
AssigneeBavarian Nordic A/S
InventorsCigdem Atay Langbein, André Riedl, Markus Kalla, Maria Hinterberger, José Medina Echeverz, Pedro Berraondo López
Estimating the term…
The invention relates to a composition and related methods for enhancing the immune response and/or decreasing the size or growth rate of a tumor volume in a subject. The composition comprises a recombinant MVA encoding IL-12 and, optionally, a Tumor Associated Antigen (“TAA”). In some embodiments, the MVA also encodes 4-1BBL and/or a second MVA encoding 4-1BBL is coadministered to the subject. In some embodiments of the invention, methods comprise injecting these MVAs intratumorally. In some embodiments, the recombinant MVAs are injected intraperitoneally to stimulate an immune response to peritoneal tumors.
1-6. (canceled)
A method for increasing an inflammatory response in a subject having a tumor, the method comprising intratumorally administering to the subject a recombinant modified Vaccinia virus Ankara (MVA) comprising a first nucleic acid encoding a tumor-associated antigen (TAA) and a second nucleic acid encoding IL-12, wherein the intratumoral administration of the recombinant MVA increases an inflammatory response in the tumor as compared to injection of MVA alone.
11-14. (canceled)
A method of inducing an increased inflammatory response in a peritoneal tumor of a subject, the method comprising intraperitoneally administering to the subject a recombinant modified Vaccinia Ankara (MVA) comprising a first nucleic acid encoding IL-12, wherein the intraperitoneal administration of the recombinant MVA generates an increased inflammatory response in the tumor as compared to an inflammatory response that would be generated by injection of MVA alone.
A recombinant modified Vaccinia Ankara (MVA), comprising:
Dependencies are inferred from the claim text.